{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,4,17]],"date-time":"2025-04-17T15:51:02Z","timestamp":1744905062404},"reference-count":12,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2019,3,18]],"date-time":"2019-03-18T00:00:00Z","timestamp":1552867200000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Hautarzt"],"published-print":{"date-parts":[[2019,6]]},"DOI":"10.1007\/s00105-019-4392-x","type":"journal-article","created":{"date-parts":[[2019,3,18]],"date-time":"2019-03-18T11:05:01Z","timestamp":1552907101000},"page":"443-446","update-policy":"http:\/\/dx.doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Mediastinale Lymphknotenvergr\u00f6\u00dferung bei einer Patientin mit malignem Melanom Stadium\u00a0IV unter Therapie mit Pembrolizumab"],"prefix":"10.1007","volume":"70","author":[{"given":"Georgios","family":"Nikolakis","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Martina","family":"Brunner","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Heike","family":"Boye","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nicole","family":"Arndt","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andreas","family":"Altenburg","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Aristeidis","family":"Vaiopoulos","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christos C.","family":"Zouboulis","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2019,3,18]]},"reference":[{"key":"4392_CR1","doi-asserted-by":"publisher","first-page":"290","DOI":"10.1016\/j.jdcr.2016.06.004","volume":"2","author":"J Cotliar","year":"2016","unstructured":"Cotliar J, Querfeld C, Boswell WJ et al (2016) Pembrolizumab-associated sarcoidosis. JAAD Case Rep 2:290\u2013293","journal-title":"JAAD Case Rep."},{"key":"4392_CR2","doi-asserted-by":"publisher","first-page":"1178","DOI":"10.1093\/annonc\/mdw125","volume":"27","author":"S Cousin","year":"2016","unstructured":"Cousin S, Toulmonde M, Kind M et al (2016) Pulmonary sarcoidosis induced by the anti-PD1 monoclonal antibody pembrolizumab. Ann Oncol 27:1178\u20131179","journal-title":"Ann Oncol"},{"key":"4392_CR3","doi-asserted-by":"publisher","first-page":"e133","DOI":"10.1016\/j.chest.2015.10.082","volume":"149","author":"FX Danlos","year":"2016","unstructured":"Danlos FX, Pages C, Baroudjian B et al (2016) Nivolumab-induced sarcoid-like granulomatous reaction in a\u00a0patient with advanced melanoma. Chest 149:e133\u2013e136","journal-title":"Chest"},{"key":"4392_CR4","doi-asserted-by":"publisher","first-page":"3193","DOI":"10.1200\/JCO.2015.60.8448","volume":"33","author":"TZ Horvat","year":"2015","unstructured":"Horvat TZ, Adel NG, Dang TO et al (2015) Immune-related adverse events, need for systemic Immunosuppression, and effects on survival and time to treatment failure in patients with melanoma treated with Ipilimumab at memorial Sloan Kettering cancer center. J\u00a0Clin Oncol 33:3193\u20133198","journal-title":"J Clin Oncol"},{"key":"4392_CR5","doi-asserted-by":"publisher","first-page":"1277","DOI":"10.1111\/1756-185X.13076","volume":"20","author":"AJ Lomax","year":"2017","unstructured":"Lomax AJ, Mcguire HM, Mcneil C et al (2017) Immunotherapy-induced sarcoidosis in patients with melanoma treated with PD-1 checkpoint inhibitors: case series and immunophenotypic analysis. Int J Rheum Dis 20:1277\u20131285","journal-title":"Int J Rheum Dis"},{"key":"4392_CR6","doi-asserted-by":"publisher","first-page":"1060","DOI":"10.1111\/bjd.14808","volume":"176","author":"H Montaudie","year":"2017","unstructured":"Montaudie H, Pradelli J, Passeron T et al (2017) Pulmonary sarcoid-like granulomatosis induced by nivolumab. Br J Dermatol 176:1060\u20131063","journal-title":"Br J Dermatol"},{"key":"4392_CR7","first-page":"565","volume":"113","author":"A Prasse","year":"2016","unstructured":"Prasse A (2016) The diagnosis, differential diagnosis, and treatment of sarcoidosis. Dtsch Arztebl Int 113:565\u2013574","journal-title":"Dtsch Arztebl Int"},{"key":"4392_CR8","doi-asserted-by":"publisher","first-page":"307","DOI":"10.1097\/CJI.0000000000000181","volume":"40","author":"SB Reddy","year":"2017","unstructured":"Reddy SB, Possick JD, Kluger HM et al (2017) Sarcoidosis following anti-PD-1 and anti-CTLA-4 therapy for metastatic melanoma. J\u00a0Immunother 40:307\u2013311","journal-title":"J Immunother"},{"key":"4392_CR9","doi-asserted-by":"publisher","first-page":"94","DOI":"10.1186\/s40425-016-0199-9","volume":"4","author":"JE Reuss","year":"2016","unstructured":"Reuss JE, Kunk PR, Stowman AM et\u00a0al (2016) Sarcoidosis in the setting of combination ipilimumab and nivolumab immunotherapy: a\u00a0case report & review of the literature. J\u00a0Immunother Cancer 4:94","journal-title":"J Immunother Cancer"},{"key":"4392_CR10","doi-asserted-by":"publisher","first-page":"321","DOI":"10.1177\/039463201402700302","volume":"27","author":"G Tchernev","year":"2014","unstructured":"Tchernev G, Cardoso JC, Chokoeva AA et\u00a0al (2014) The \u201emystery\u201c of cutaneous sarcoidosis: facts and controversies. Int J Immunopathol Pharmacol 27:321\u2013330","journal-title":"Int J Immunopathol Pharmacol"},{"key":"4392_CR11","doi-asserted-by":"publisher","first-page":"523","DOI":"10.1097\/DAD.0000000000001066","volume":"40","author":"R Woodbeck","year":"2018","unstructured":"Woodbeck R, Metelitsa AI, Naert KA (2018) Granulomatous tumoral melanosis associated with pembrolizumab therapy: a mimicker of disease progression in metastatic melanoma. Am J Dermatopathol 40:523\u2013526","journal-title":"Am J Dermatopathol"},{"key":"4392_CR12","doi-asserted-by":"publisher","first-page":"130","DOI":"10.1016\/j.revmed.2017.11.008","volume":"39","author":"N Yatim","year":"2018","unstructured":"Yatim N, Mateus C, Charles P (2018) Sarcoidosis post-anti-PD-1 therapy, mimicking relapse of metastatic melanoma in a\u00a0patient undergoing complete remission. Rev Med Interne 39:130\u2013133","journal-title":"Rev Med Interne"}],"container-title":["Der Hautarzt"],"original-title":[],"language":"de","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00105-019-4392-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00105-019-4392-x\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00105-019-4392-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,3,17]],"date-time":"2020-03-17T00:21:30Z","timestamp":1584404490000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00105-019-4392-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,3,18]]},"references-count":12,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2019,6]]}},"alternative-id":["4392"],"URL":"https:\/\/doi.org\/10.1007\/s00105-019-4392-x","relation":{},"ISSN":["0017-8470","1432-1173"],"issn-type":[{"value":"0017-8470","type":"print"},{"value":"1432-1173","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,3,18]]},"assertion":[{"value":"18 March 2019","order":1,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Einhaltung ethischer Richtlinien"}},{"value":"G.\u00a0Nikolakis, M.\u00a0Brunner, H.\u00a0Boye, N.\u00a0Arndt, A.\u00a0Altenburg, A.\u00a0Vaiopoulos und C.C.\u00a0Zouboulis geben an, dass kein Interessenkonflikt besteht.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Interessenkonflikt"}},{"value":"Dieser Beitrag beinhaltet keine von den Autoren durchgef\u00fchrten Studien an Menschen oder Tieren. F\u00fcr Bildmaterial oder anderweitige Angaben innerhalb des Manuskripts, \u00fcber die Patienten zu identifizieren sind, liegt von ihnen und\/oder ihren gesetzlichen Vertretern eine schriftliche Einwilligung vor.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Interessenkonflikt"}}]}}